Alopecia Treatment Market Reaches USD 11.38 Billion in 2026, Driven by Rising Prevalence of Hair Loss Disorders

Novel Drug Approvals, Regenerative Therapies, and Technological Innovations to Drive Alopecia Treatment Market to USD 16.89 Billion by 2033 at 5.8% CAGR – Coherent Market Insights

The Alopecia Treatment Market, estimated at USD 11.38 Bn in 2026, is expected to exhibit a CAGR of 5.8% and reach USD 16.89 Bn by 2033.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Increasing awareness for the treatment of alopecia is expecetd to drive the global alopecia treatment market growth. For instance, in September 2025, National Alopecia Areata Foundation (NAAF) serves the community of people affected by an autoimmune skin disease called alopecia areata that results in hair loss and emotional pain, will orchestrate a nationwide (U.S.) fund raising initiative, spanning from coast to coast, dedicated to generating resources, bolstering community support, fostering public awareness, and empowering individuals affected by alopecia areata. This year (2025), the foundation will centrally organize a walk event at Lake Merced in San Francisco, CA, in commemoration of the community where NAAF was originally established over four decades ago. Concurrently, we will facilitate independent "Walk Where You Are" teams in various localities across the nation, offering an inclusive opportunity for individuals from all regions to actively engage with the cause of alopecia areata.

Global Alopecia Treatment Market: Key Developments

• In April 2026, Priovant initiated enrollment in a seamless Phase 2b/3 clinical trial evaluating oral brepocitinib for lichen planopilaris, a rare inflammatory scalp disorder causing permanent scarring alopecia. The first patients were dosed in March 2026. The potentially registrational study will assess whether dual JAK1 and TYK2 inhibition can control inflammation, preserve hair follicles, and address a major treatment gap, as no therapies are currently approved specifically for lichen planopilaris.
• In March 2026, Pelage Pharmaceuticals presented PP405 research at the American Academy of Dermatology Annual Meeting. The investigational topical therapy targets a metabolic switch within dormant hair-follicle stem cells, aiming to restart the natural hair-growth cycle without relying on hormonal mechanisms. Late-stage clinical studies are planned during 2026. (Source: Pelage Pharmaceuticals)
• In May 2026, Lumenis announced the presentation of two pivotal studies evaluating FoLix, its FDA-cleared non-ablative fractional laser treatment for hair loss. The technology stimulates natural follicular activity through fractional laser energy and offers a chemical-free, minimally invasive option for male and female patients.
• In May 2026, Aquestive Therapeutics, pharmaceutical company reported continued development planning for AQST-108, a topical epinephrine prodrug platform with potential applications across dermatological conditions, including alopecia areata. The program represents an innovative drug-delivery approach intended to improve localized therapeutic exposure.
• In January 2025, CorEvitas, LLC, the leading sponsor of syndicated clinical registries in autoimmune and inflammatory diseases, launched its ninth clinical registry and is recruiting patients in a first-of-its-kind registry to evaluate the safety and effectiveness of newly approved therapies for patients diagnosed with alopecia areata. This unique initiative leverages the company's high-caliber dermatology site network to address an unmet need for real-world evidence (RWE) and safety data related to novel therapies for alopecia areata.
• In March 2025, Mount Sinai Health System,  a hospital network in New York City, launched new Alopecia Areata Center of Excellence. In an unparalleled effort to deliver outstanding comprehensive care and to employ revolutionary approaches to novel therapeutics around the skin condition alopecia areata, the Mount Sinai Health System has launched the Alopecia Areata Center of Excellence.

Browse 34 Market Data Tables and 24 Figures spread through 180 Pages and in-depth TOC on “Global Alopecia Treatment Market”- Forecast to 2033, Global Alopecia Treatment Market,  By Drug Class (Corticosteroids, 5 AR Inhibitors, Vasodilators and Others), By Disease Type (Alopecia Areata, Androgenic Alopecia,  Traction Alopecia and Others), By Route of Administration (Topical, Oral, and Injectable ), By Distribution Channel (Hospital Pharmacies, Retail  Pharmacies, and Online  Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/alopecia-treatment-market-1847

Key Takeaways of the Global Alopecia Treatment Market

• Global alopecia treatment market is expected to exhibit a CAGR of 5.8% during the forecast period. The increasing prevalence of alopecia will increase demand of its treatment thus, driving the market growth over the forecast period.
• Among drug class, the corticosteroids segment is expected to hold a dominant position in the global alopecia treatment market during the forecast period, and this is attributed to the Inorganic growth strategies such as acquisition and collaboration by market players for alopecia treatment. Corticosteroids are a class of anti-inflammatory medications that can be used in the treatment of various conditions, including alopecia (hair loss). Corticosteroids work by suppressing the immune system and reducing inflammation, which can be beneficial in certain types of alopecia where inflammation plays a role in hair loss.
• Among disease type, alopecia areata is expected have the highest CAGR in the global alopecia treatment market, owing to market players focusing on increasing research and development activities for alopecia areata treatment. For instance, in September 2025, Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc, a global biotechnology company, announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata. Q32 Bio and Horizon are collaborating to develop bempikibart, a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, two key immune pathways.
• The major players operating in the global alopecia treatment market are Stemson Therapeutics, OliX Pharmaceuticals, Inc, Pfizer Inc, Aclaris Therapeutics, Inc., Fagron, Follicum AB, Cipla Inc., Arcutis Biotherapeutics, Dr. Reddy’s Laboratories Ltd., Himalaya Wellness Company, Cosmo Pharmaceuticals N.V., Equillium, Inc., Eli Lilly and Company, Concert Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.